Investigator
Kent State University
Visible light-activatable platinum(iv) prodrugs harnessing CD36 for ovarian cancer therapy
Visible light-activatable Pt(iv) prodrugs harness the upregulated CD36 to facilitate cell entry and killing of drug resistant ovarian cancer cells.
Fatty acid-like Pt(iv) prodrugs overcome cisplatin resistance in ovarian cancer by harnessing CD36
The fatty acid-like Pt(iv) prodrugs act as a “Trojan horse” to exploit upregulated CD36 receptors to facilitate their entry to ovarian cancer cells.
